medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2025, Número 4

<< Anterior Siguiente >>

Rev Mex Urol 2025; 85 (4)


El transcriptoma en cáncer de próstata, una herramienta molecular de diagnóstico

Vargas-Castellanos E, Rincón-Riveros A

Idioma: Español
Referencias bibliográficas: 74
Paginas: 1-17
Archivo PDF: 393.78 Kb.


RESUMEN

El cáncer de próstata es una causa importante de muerte relacionada con el cáncer en hombres. La detección temprana es crucial para combatir la enfermedad. La secuenciación del ARN es una técnica que ha revolucionado nuestra comprensión del transcriptoma humano y ahora es una herramienta útil para identificar biomarcadores que ayudan en el diagnóstico, el pronóstico y el seguimiento del tratamiento del cáncer. Este artículo tiene como objetivo explorar cómo el transcriptoma se ha convertido en una herramienta prometedora para guiar las decisiones clínicas, especialmente en la vigilancia activa y el uso de tratamientos adyuvantes en el cáncer de próstata.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bray F, Laversanne M, Sung H, Ferlay J,Siegel RL, Soerjomataram I, et al. Globalcancer statistics 2022: GLOBOCAN estimatesof incidence and mortality worldwide for 36cancers in 185 countries. CA: a cancer journalfor clinicians. 2024;74(3): 229–263. https://doi.org/10.3322/caac.21834.

  2. Schafer EJ, Laversanne M, Sung H,Soerjomataram I, Briganti A, Dahut W, et al.Recent Patterns and Trends in Global ProstateCancer Incidence and Mortality: An Update.European Urology. 2025;87(3): 302–313.https://doi.org/10.1016/j.eururo.2024.11.013.

  3. Pernar CH, Ebot EM, Wilson KM, MucciLA. The Epidemiology of Prostate Cancer.Cold Spring Harbor Perspectives in Medicine.2018;8(12): a030361. https://doi.org/10.1101/cshperspect.a030361.

  4. Filella X, Fernández-Galan E, FernándezBonifacio R, Foj L. Emerging biomarkers in thediagnosis of prostate cancer. Pharmacogenomicsand Personalized Medicine. 2018;11: 83–94.https://doi.org/10.2147/PGPM.S136026.

  5. Zelic R, Garmo H, Zugna D, Stattin P,Richiardi L, Akre O, et al. Predicting ProstateCancer Death with Different PretreatmentRisk Stratification Tools: A Head-to-headComparison in a Nationwide Cohort Study.European Urology. 2020;77(2): 180–188.https://doi.org/10.1016/j.eururo.2019.09.027.

  6. Cancer Genome Atlas Research Network.The Molecular Taxonomy of Primary ProstateCancer. Cell. 2015;163(4): 1011–1025. https://doi.org/10.1016/j.cell.2015.10.025.

  7. Swanton C. Intratumor heterogeneity:evolution through space and time. CancerResearch. 2012;72(19): 4875–4882. https://doi.org/10.1158/0008-5472.CAN-12-2217.

  8. Rousseaux S, Debernardi A, Jacquiau B,Vitte AL, Vesin A, Nagy-Mignotte H, et al.Ectopic activation of germline and placentalgenes identifies aggressive metastasispronelung cancers. Science TranslationalMedicine. 2013;5(186): 186ra66. https://doi.org/10.1126/scitranslmed.3005723.

  9. Barrett CL, DeBoever C, Jepsen K, SaenzCC, Carson DA, Frazer KA. Systematictranscriptome analysis reveals tumor-specificisoforms for ovarian cancer diagnosis andtherapy. Proceedings of the National Academyof Sciences of the United States of America.2015;112(23): E3050–E3057. https://doi.org/10.1073/pnas.1508057112.

  10. Zhao S, Fung-Leung WP, Bittner A, Ngo K, LiuX. Comparison of RNA-Seq and Microarray inTranscriptome Profiling of Activated T Cells.PLOS ONE. 2014;9(1): e78644. https://doi.org/10.1371/journal.pone.0078644.

  11. Howbrook DN, van der Valk AM,O’Shaughnessy MC, Sarker DK, Baker SC,Lloyd AW. Developments in microarraytechnologies. Drug Discovery Today. 2003;8(14):642–651. https://doi.org/10.1016/s1359-6446(03)02773-9.

  12. Mantione KJ, Kream RM, Kuzelova H,Ptacek R, Raboch J, Samuel JM, et al.Comparing Bioinformatic Gene ExpressionProfiling Methods: Microarray and RNASeq.Medical Science Monitor Basic Research.2014;20: 138–141. https://doi.org/10.12659/MSMBR.892101.

  13. Farhangfar CJ, Meric-Bernstam F,Mendelsohn J, Mills GB, Lucio-EterovicAK. The impact of tumor heterogeneity onpatient treatment decisions. Clinical Chemistry.2013;59(1): 38–40. https://doi.org/10.1373/clinchem.2012.194712.

  14. Samborski A, Miller MC, Blackman A,MacLaughlan-David S, Jackson A, Lambert-Messerlian G, et al. HE4 and CA125 serumbiomarker monitoring in women with epithelialovarian cancer. Tumour Biology: The Journal ofthe International Society for OncodevelopmentalBiology and Medicine. 2022;44(1): 205–213.https://doi.org/10.3233/TUB-220016.

  15. Thienger P, Rubin MA. Prostate cancer hijacksthe microenvironment. Nature Cell Biology.2021;23(1): 3–5. https://doi.org/10.1038/s41556-020-00616-3.

  16. Salachan PV, Rasmussen M, Ulhøi BP, JensenJB, Borre M, Sørensen KD. Spatial wholetranscriptome profiling of primary tumorfrom patients with metastatic prostate cancer.International Journal of Cancer. 2023;153(12):2055–2067. https://doi.org/10.1002/ijc.34708.

  17. Yu X, Liu R, Gao W, Wang X, Zhang Y. Singlecellomics traces the heterogeneity of prostatecancer cells and the tumor microenvironment.Cellular & Molecular Biology Letters. 2023;28(1):38. https://doi.org/10.1186/s11658-023-00450-z.

  18. Cieślik M, Chinnaiyan AM. Cancertranscriptome profiling at the juncture ofclinical translation. Nature Reviews. Genetics.2018;19(2): 93–109. https://doi.org/10.1038/nrg.2017.96.

  19. Creighton CJ. Gene Expression Profilesin Cancers and Their TherapeuticImplications. Cancer Journal (Sudbury, Mass.).

  20. 2023;29(1): 9–14. https://doi.org/10.1097/PPO.0000000000000638.20. Haffner MC, Zwart W, Roudier MP, True LD,Nelson WG, Epstein JI, et al. Genomic andphenotypic heterogeneity in prostate cancer.Nature Reviews. Urology. 2021;18(2): 79–92.https://doi.org/10.1038/s41585-020-00400-w.

  21. Kristiansen G. Diagnostic and prognosticmolecular biomarkers for prostate cancer.Histopathology. 2012;60(1): 125–141. https://doi.org/10.1111/j.1365-2559.2011.04083.x.

  22. Schaeffer E, Srinivas S, Antonarakis ES,Armstrong AJ, Bekelman JE, Cheng H,et al. NCCN Guidelines Insights: ProstateCancer, Version 1.2021. Journal of the NationalComprehensive Cancer Network: JNCCN.2021;19(2): 134–143. https://doi.org/10.6004/jnccn.2021.0008.

  23. Modelska A, Quattrone A, Re A. Molecularportraits: the evolution of the concept oftranscriptome-based cancer signatures.Briefings in Bioinformatics. 2015;16(6): 1000–1007. https://doi.org/10.1093/bib/bbv013.

  24. Hong M, Tao S, Zhang L, Diao LT, Huang X,Huang S, et al. RNA sequencing: new technologiesand applications in cancer research. Journal ofHematology & Oncology. 2020;13(1): 166. https://doi.org/10.1186/s13045-020-01005-x.

  25. Oshlack A, Robinson MD, Young MD. FromRNA-seq reads to differential expression results.Genome Biology. 2010;11(12): 220. https://doi.org/10.1186/gb-2010-11-12-220.

  26. Lu Y, Beeghly-Fadiel A, Wu L, Guo X, Li B,Schildkraut JM, et al. A Transcriptome-WideAssociation Study Among 97,898 Womento Identify Candidate Susceptibility Genesfor Epithelial Ovarian Cancer Risk. CancerResearch. 2018;78(18): 5419–5430. https://doi.org/10.1158/0008-5472.CAN-18-0951.

  27. Parra-Medina R, López-Kleine L, Ramírez-Clavijo S, Payán-Gómez C. Identification ofcandidate miRNAs in early-onset and late-onsetprostate cancer by network analysis. ScientificReports. 2020;10(1): 12345. https://doi.org/10.1038/s41598-020-69290-7.

  28. Singh B, Trincado JL, Tatlow PJ, Piccolo SR,Eyras E. Genome Sequencing and RNA-MotifAnalysis Reveal Novel Damaging NoncodingMutations in Human Tumors. Molecular cancerresearch: MCR. 2018;16(7): 1112–1124. https://doi.org/10.1158/1541-7786.MCR-17-0601.

  29. Ma X, Guo J, Liu K, Chen L, Liu D, DongS, et al. Identification of a distinct luminalsubgroup diagnosing and stratifying early stageprostate cancer by tissue-based single-cell RNAsequencing. Molecular Cancer. 2020;19(1): 147.https://doi.org/10.1186/s12943-020-01264-9.

  30. Brady L, Kriner M, Coleman I, Morrissey C,Roudier M, True LD, et al. Inter- and intratumorheterogeneity of metastatic prostatecancer determined by digital spatial geneexpression profiling. Nature Communications.2021;12(1): 1426. https://doi.org/10.1038/s41467-021-21615-4.

  31. Akhoundova D, Feng FY, Pritchard CC, RubinMA. Molecular Genetics of Prostate Cancer andRole of Genomic Testing. Surgical PathologyClinics. 2022;15(4): 617–628. https://doi.org/10.1016/j.path.2022.08.002.

  32. Rubin MA, Girelli G, Demichelis F. GenomicCorrelates to the Newly Proposed GradingPrognostic Groups for Prostate Cancer. EuropeanUrology. 2016;69(4): 557–560. https://doi.org/10.1016/j.eururo.2015.10.040.

  33. Lapointe J, Li C, Higgins JP, van de Rijn M,Bair E, Montgomery K, et al. Gene expressionprofiling identifies clinically relevant subtypesof prostate cancer. Proceedings of the NationalAcademy of Sciences of the United States ofAmerica. 2004;101(3): 811–816. https://doi.org/10.1073/pnas.0304146101.

  34. Strømme JM, Johannessen B, Kidd SG,Bogaard M, Carm KT, Zhang X, et al.Expressed prognostic biomarkers for primaryprostate cancer independent of multifocalityand transcriptome heterogeneity. Cancer GeneTherapy. 2022;29(8–9): 1276–1284. https://doi.org/10.1038/s41417-022-00444-7.

  35. St. John J, Powell K, Conley-LaComb MK,Chinni SR. TMPRSS2-ERG Fusion GeneExpression in Prostate Tumor Cells and ItsClinical and Biological Significance in ProstateCancer Progression. Journal of cancer science& therapy. 2012;4(4): 94–101. https://doi.org/10.4172/1948-5956.1000119.

  36. Fernández-Serra A, Rubio-Briones J, García-Casado Z, Solsona E, López-GuerreroJA. [Prostate cancer: the revolution of thefusion genes]. Actas Urologicas Espanolas.2011;35(7): 420–428. https://doi.org/10.1016/j.acuro.2010.11.019.

  37. Cotter K, Rubin MA. The evolving landscape ofprostate cancer somatic mutations. The Prostate.2022;82 Suppl 1(Suppl 1): S13–S24. https://doi.org/10.1002/pros.24353.

  38. Kobelyatskaya AA, Pudova EA, Katunina IV,Snezhkina AV, Fedorova MS, Pavlov VS, et al.Transcriptome Profiling of Prostate Cancer,Considering Risk Groups and the TMPRSS2-ERG Molecular Subtype. International Journal ofMolecular Sciences. 2023;24(11): 9282. https://doi.org/10.3390/ijms24119282.

  39. Minner S, Gärtner M, Freudenthaler F,Bauer M, Kluth M, Salomon G, et al. Markedheterogeneity of ERG expression in largeprimary prostate cancers. Modern Pathology: AnOfficial Journal of the United States and CanadianAcademy of Pathology, Inc. 2013;26(1): 106–116.https://doi.org/10.1038/modpathol.2012.130.

  40. Barry M, Perner S, Demichelis F, RubinMA. TMPRSS2-ERG fusion heterogeneity inmultifocal prostate cancer: clinical and biologicimplications. Urology. 2007;70(4): 630–633.https://doi.org/10.1016/j.urology.2007.08.032.

  41. Schimmelpfennig C, Rade M, Füssel S, LöfflerD, Blumert C, Bertram C, et al. Characterizationand evaluation of gene fusions as a measureof genetic instability and disease prognosis inprostate cancer. BMC cancer. 2023;23(1): 575.https://doi.org/10.1186/s12885-023-11019-6.

  42. Kral M, Kurfurstova D, Zemla P, Elias M,Bouchal J. New biomarkers and multiplex testsfor diagnosis of aggressive prostate cancer andtherapy management. Frontiers in Oncology.2025;15: 1542511. https://doi.org/10.3389/fonc.2025.1542511.

  43. Roidos C, Anastasiadis A, Tsiakaras S,Loutradis C, Baniotis P, Memmos D, et al.Integration of Genomic Tests in Prostate CancerCare: Implications for Clinical Practice andPatient Outcomes. Current Issues in MolecularBiology. 2024;46(12): 14408–14421. https://doi.org/10.3390/cimb46120864.

  44. Liu HE, Vuppalapaty M, Hoerner CR,Bergstrom CP, Chiu M, Lemaire C, et al.Detecting androgen receptor (AR), AR variant7 (AR-V7), prostate-specific membrane antigen(PSMA), and prostate-specific antigen (PSA)gene expression in CTCs and plasma exosomederivedcfRNA in patients with metastaticcastration-resistant prostate cancer (mCRPC)by integrating the VTX-1 CTC isolation systemwith the QIAGEN AdnaTest. BMC cancer.2024;24(1): 482. https://doi.org/10.1186/s12885-024-12139-3.

  45. Antonarakis ES, Lu C, Wang H, Luber B,Nakazawa M, Roeser JC, et al. AR-V7 andResistance to Enzalutamide and Abirateronein Prostate Cancer. New England Journal ofMedicine. 2014;371(11): 1028–1038. https://doi.org/10.1056/NEJMoa1315815.

  46. Feng FY, Huang HC, Spratt DE, Zhao SG,Sandler HM, Simko JP, et al. Validation of a22-Gene Genomic Classifier in Patients WithRecurrent Prostate Cancer: An Ancillary Studyof the NRG/RTOG 9601 Randomized ClinicalTrial. JAMA oncology. 2021;7(4): 544–552.https://doi.org/10.1001/jamaoncol.2020.7671.

  47. Cuzick J, Swanson GP, Fisher G, BrothmanAR, Berney DM, Reid JE, et al. Prognosticvalue of an RNA expression signature derivedfrom cell cycle proliferation genes in patientswith prostate cancer: a retrospective study. TheLancet. Oncology. 2011;12(3): 245–255. https://doi.org/10.1016/S1470-2045(10)70295-3.

  48. Tosoian JJ, Zhang Y, Xiao L, Xie C, Samora NL,Niknafs YS, et al. Development and Validation ofan 18-Gene Urine Test for High-Grade ProstateCancer. JAMA oncology. 2024;10(6): 726–736.https://doi.org/10.1001/jamaoncol.2024.0455.

  49. Klein EA, Cooperberg MR, Magi-GalluzziC, Simko JP, Falzarano SM, Maddala T, etal. A 17-gene assay to predict prostate canceraggressiveness in the context of Gleasongrade heterogeneity, tumor multifocalityand biopsy undersampling. European Urology.2014;66(3): 550–560. https://doi.org/10.1016/j.eururo.2014.05.004.

  50. Tutrone R, Donovan MJ, Torkler P, Tadigotla V,McLain T, Noerholm M, et al. Clinical utility ofthe exosome based ExoDx Prostate(IntelliScore)EPI test in men presenting for initial Biopsy witha PSA 2-10 ng/mL. Prostate Cancer and ProstaticDiseases. 2020;23(4): 607–614. https://doi.org/10.1038/s41391-020-0237-z.

  51. Maggi M, Del Giudice F, Falagario UG, CocciA, Russo GI, Di Mauro M, et al. SelectMDx andMultiparametric Magnetic Resonance Imagingof the Prostate for Men Undergoing PrimaryProstate Biopsy: A Prospective Assessmentin a Multi-Institutional Study. Cancers.2021;13(9): 2047. https://doi.org/10.3390/cancers13092047.

  52. Durand X, Moutereau S, Xylinas E, de laTaille A. ProgensaTM PCA3 test for prostatecancer. Expert Review of Molecular Diagnostics.2011;11(2): 137–144. https://doi.org/10.1586/erm.10.122.

  53. Ma C, Zhou Y, Fanelli GN, Stopsack KH,Fiorentino M, Zadra G, et al. The ProstateStromal Transcriptome in Aggressive and LethalProstate Cancer. Molecular cancer research:MCR. 2023;21(3): 253–260. https://doi.org/10.1158/1541-7786.MCR-22-0627.

  54. Aran D, Camarda R, Odegaard J, Paik H,Oskotsky B, Krings G, et al. Comprehensiveanalysis of normal adjacent to tumortranscriptomes. Nature Communications.2017;8(1): 1077. https://doi.org/10.1038/s41467-017-01027-z.

  55. Hernandez G. Cáncer de próstata: Conceptosbiomoleculares Prostate cancer: Biomolecularconcepts. Carcinos. 2014;4(2). h

  56. Feng D, Xiong Q, Wei Q, Yang L. Cellularlandscape of tumour microenvironment inprostate cancer. Immunology. 2023;168(2):199–202. https://doi.org/10.1111/imm.13456.

  57. Bu L, Baba H, Yoshida N, Miyake K, YasudaT, Uchihara T, et al. Biological heterogeneityand versatility of cancer-associated fibroblastsin the tumor microenvironment. Oncogene.2019;38(25): 4887–4901. https://doi.org/10.1038/s41388-019-0765-y.

  58. Mhaidly R, Mechta-Grigoriou F. Fibroblastheterogeneity in tumor micro-environment:Role in immunosuppression and new therapies.Seminars in Immunology. 2020;48: 101417.https://doi.org/10.1016/j.smim.2020.101417.

  59. Loeb S, Vellekoop A, Ahmed HU, Catto J,Emberton M, Nam R, et al. Systematic reviewof complications of prostate biopsy. EuropeanUrology. 2013;64(6): 876–892. https://doi.org/10.1016/j.eururo.2013.05.049.

  60. Cooper CS, Eeles R, Wedge DC, Van Loo P,Gundem G, Alexandrov LB, et al. Analysis ofthe genetic phylogeny of multifocal prostatecancer identifies multiple independent clonalexpansions in neoplastic and morphologicallynormal prostate tissue. Nature Genetics.2015;47(4): 367–372. https://doi.org/10.1038/ng.3221.

  61. Jeon J, Olkhov-Mitsel E, Xie H, Yao CQ, ZhaoF, Jahangiri S, et al. Temporal Stability andPrognostic Biomarker Potential of the ProstateCancer Urine miRNA Transcriptome. Journal ofthe National Cancer Institute. 2020;112(3): 247–255. https://doi.org/10.1093/jnci/djz112.

  62. Cortese R, Kwan A, Lalonde E, BryzgunovaO, Bondar A, Wu Y, et al. Epigenetic markersof prostate cancer in plasma circulating DNA.Human Molecular Genetics. 2012;21(16): 3619–3631. https://doi.org/10.1093/hmg/dds192.

  63. Salido-Guadarrama AI, Morales-MontorJG, Rangel-Escareño C, Langley E, Peralta-Zaragoza O, Cruz Colin JL, et al. UrinarymicroRNA-based signature improves accuracyof detection of clinically relevant prostatecancer within the prostate-specific antigen greyzone. Molecular Medicine Reports. 2016;13(6):4549–4560. https://doi.org/10.3892/mmr.2016.5095.

  64. Peng Y, Croce CM. The role of MicroRNAsin human cancer. Signal Transduction andTargeted Therapy. 2016;1: 15004. https://doi.org/10.1038/sigtrans.2015.4.

  65. Stavast CJ, Erkeland SJ. The Non-CanonicalAspects of MicroRNAs: Many Roads to GeneRegulation. Cells. 2019;8(11): 1465. https://doi.org/10.3390/cells8111465.

  66. Rana S, Valbuena GN, Curry E, Bevan CL,Keun HC. MicroRNAs as biomarkers forprostate cancer prognosis: a systematic reviewand a systematic reanalysis of public data.British Journal of Cancer. 2022;126(3): 502–513.https://doi.org/10.1038/s41416-021-01677-3.

  67. Chen S, Lu C, Lin S, Sun C, Wen Z, Ge Z, et al.A panel based on three-miRNAs as diagnosticbiomarker for prostate cancer. Frontiers inGenetics. 2024;15. https://doi.org/10.3389/fgene.2024.1371441.

  68. Statello L, Guo CJ, Chen LL, Huarte M. Generegulation by long non-coding RNAs and itsbiological functions. Nature Reviews. MolecularCell Biology. 2021;22(2): 96–118. https://doi.org/10.1038/s41580-020-00315-9.

  69. Bridges MC, Daulagala AC, Kourtidis A.LNCcation: lncRNA localization and function.The Journal of Cell Biology. 2021;220(2):e202009045. https://doi.org/10.1083/jcb.202009045.

  70. Ferreira LB, Palumbo A, de Mello KD,Sternberg C, Caetano MS, de Oliveira FL, et al.PCA3 noncoding RNA is involved in the controlof prostate-cancer cell survival and modulatesandrogen receptor signaling. BMC cancer.2012;12: 507. https://doi.org/10.1186/1471-2407-12-507.

  71. Lemos AEG, Matos A da R, Ferreira LB,Gimba ERP. The long non-coding RNAPCA3: an update of its functions and clinicalapplications as a biomarker in prostate cancer.Oncotarget. 2019;10(61): 6589–6603. https://doi.org/10.18632/oncotarget.27284.

  72. Zhao S, Prensner JR, Erho N, Ghadessi M,Yousefi K, Wellman H, et al. Identificationand Validation of the Long Noncoding RNASChLAP1 as a Prognostic Biomarker in ProstateCancer. International Journal of RadiationOncology, Biology, Physics. 2014;90(1): S2.https://doi.org/10.1016/j.ijrobp.2014.06.020.

  73. Prensner JR, Iyer MK, Sahu A, Asangani IA,Cao Q, Patel L, et al. The long noncoding RNASChLAP1 promotes aggressive prostate cancerand antagonizes the SWI/SNF complex. NatureGenetics. 2013;45(11): 1392–1398. https://doi.org/10.1038/ng.2771.

  74. Parra-Medina R, López-Kleine L, Ramírez-Clavijo S, Payán-Gómez C. Coexpressionnetwork analysis identified lncRNAs-mRNAswith potential relevance in African ancestryprostate cancer. Future science OA. 2021;7(9):FSO749. https://doi.org/10.2144/fsoa-2021-0076.




2020     |     www.medigraphic.com